This study examined the effect of single dose etofibrate (1.0 g/day) on plasma lipids and lipoproteins in a group of eleven hypercholesterolemic individuals. The drug lowered plasma triglyceride and cholesterol by 32% and 14%, respectively (P less than 0.005). The cholesterol reduction came from a decrement in both VLDL and LDL. The cholesterol content of HDL did not change although its mass as determined by analytical ultracentrifugation rose by 29%. LDL metabolism was followed before and during drug therapy. Treatment increased catabolism of this lipoprotein by 14%, without affecting synthesis. The increased clearance resulted from activation (64%) of the LDL receptor pathway. There was a reciprocal decrease in the amount of lipoprotein channelled into the receptor-independent route.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0021-9150(88)90019-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Emerging contaminants as indicators of short-term environmental changes in an eutrophicated coastal lagoon.
Mar Pollut Bull
December 2024
LABMAM/Department of Chemistry, Pontifícia Universidade Católica do Rio de Janeiro, 22453-900 Rio de Janeiro, Brazil. Electronic address:
This research aimed to assess the potential of emerging contaminants as environmental quality indicators for short-term monitoring programs, in contrast with traditional contaminants. Thirteen sediment samples from from Piratininga, a coastal lagoon subjected to anthropogenic impact, were analyzed for the following compounds: napropamide, diclofenac, naproxen, triclosan, ibuprofen, 17β-estradiol, bisphenol A, nadolol, ethofibrate and carbamazepine. The developed method, which included solid phase extraction, derivatization, and analysis by gas chromatography-mass spectrometry, demonstrated robustness and suitability with quantification limits between 0.
View Article and Find Full Text PDFEtofibrate enhances 123I-LDL-binding in human liver.
Hell J Nucl Med
June 2009
Institute of Nuclear Medicine, University of Perugia, Italy.
Etofibrate, a combination of fibric and nicotinic acid, is successfully used for the treatment of type IIb and IV hyperlipidemia. While an up-regulation of specific low density lipoproteins (LDL) binding sites in human platelets has been demonstrated, action on LDL-binding to the liver in patients and kinetic studies rare. This study aimed to investigate the influence of twice 500mg etofibrate daily given for 6 weeks on the in vivo binding of autologous LDL to the liver in 11 patients, 6 males, 5 females; aged 37-57 years, suffering from mixed hyperlipidemia.
View Article and Find Full Text PDFInfluence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia.
Exp Clin Endocrinol Diabetes
September 2003
Department of Internal Medicine II, Grosshadern, University of Munich, Munich, Germany.
Low density lipoprotein (LDL-) particles can be subfractionated in large-buoyant (lb), intermediate-dense (id) and small-dense (sd) LDL-subtypes. Fibrates improve the LDL-subtype profile by reducing proatherogenic sd-LDL which are prominent in diabetic dyslipoproteinemia. We evaluated the effect of etofibrate on the LDL-subtype distribution in patients with type 2 diabetes mellitus (n = 13, 55 +/- 18 years, BMI 27.
View Article and Find Full Text PDFEtofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
Int J Clin Pharmacol Res
September 1999
Regional Center for Atherosclerosis Research, Pomeranian Academy of Medicine, Szczecin, Poland.
Etofibrate is a hypolipemic drug belonging to the fibrate class. By improving the lipid profile, these drugs often exert a favorable influence on hemostatic risk factors of ischemic heart disease. We present a pilot study on the influence of etofibrate on lipids and lipoproteins in serum, as well as on factor VII and fibrinogen.
View Article and Find Full Text PDFBackground: The aim of this pilot study was to investigate the influence of a lipid lowering therapy with etofibrate on the progression of diabetic background retinopathy in patients with diabetes mellitus and combined hyperlipoproteinemia. In addition to the well known correlation between the duration of diabetes and the quality of blood glucose control, a correlation between diabetic microangiopathy and elevated triglyceride levels is discussed for many years. The most important pathogenic mechanisms in this respect seem to be an elevation of blood viscosity and alterations in the fibrinolytic system.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!